MedTrace Logo

The Effect of Neostigmine and Sugammadex on the Optic Nerve Sheath Diameter

NCT07666984 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2026-06-24

No results posted yet for this study

Summary

This study will compare how two drugs, sugammadex and neostigmine-used to reverse muscle relaxation after surgery-affect the size of the optic nerve sheath (the nerve behind the eye) as patients wake up and have their breathing tubes removed. It will also examine the relationship between changes in blood pressure and heart rate during this time and these measurements. This study will be conducted on 86 healthy patients aged 18-65 who will undergo planned surgery at the Çukurova University Faculty of Medicine, Department of Anesthesiology and Reanimation. Patients will be randomly divided into two groups: the sugammadex group and the neostigmine group. All patients will receive standard general anesthesia and rocuronium to relax their muscles. At the end of the surgery, to reverse this effect, patients will be given either sugammadex or a mix of neostigmine and atropine. Group S will receive 2 mg sugammadex per kg, while Group N will receive 0.05 mg neostigmine and 0.02 mg atropine per kg. The width of the optic nerve sheath will be measured by ultrasound 5 minutes after the breathing tube is inserted, 5 minutes before the tube is removed, and 5 minutes after it is removed. Additionally, blood pressure, heart rate, and any complications during the surgery will be tracked and compared between the groups.

Conditions

  • Neuromuscular Blockade Reversal Agent

Interventions

DRUG

Sugammadex 2 mg/kg

Intravenous bolus injection

DRUG

Neostigmine + Atropine

Intravenous bolus injection

Sponsors & Collaborators

  • Cukurova University

    lead OTHER

Principal Investigators

  • Ersel Gulec, MD · Cukurova University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-04
Primary Completion
2026-07-10
Completion
2026-07-10

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07666984 on ClinicalTrials.gov